We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Covance Acquires Signet Laboratories

Covance Acquires Signet Laboratories

Covance Acquires Signet Laboratories

Covance Acquires Signet Laboratories

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Covance Acquires Signet Laboratories"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Covance Inc. has announced that it has acquired substantially all of the assets of Signet Laboratories, Inc. for $8.95 million.

"This acquisition strengthens Covance's leadership position in providing antibodies and detection reagents that support early drug development discovery work," said Joe Herring, Covance Chairman and CEO.

"These new service offerings will allow us to tap into commercial opportunities in the pharmaceutical and clinical diagnostics markets."

"We look forward to integrating these new products and services in our drug development portfolio, and in particular with our industry leading preclinical and central laboratory services."

"Signet's outstanding line of immunological diagnostic kits and reagents enhances Covances well-established line of antibodies for neuroscience, neurodegenerative disease research, and epitope tags," said Tony Cork, Corporate Senior Vice President and co-President of Early Development.

"We are excited to welcome Signet employees to Covance as they help us deliver enhanced solutions to our clients engaged in discovery and early-phase drug development studies."